Cheaper flowsheets and a crowded Wednesday of AGMs
Oriole's scoping work on Bibemi in Cameroon is the kind of unglamorous update that matters: swapping an autoclave for ultra-fine grinding cuts sulphide plant capex by 38%. Elsewhere it was mostly housekeeping, with Sovereign and Berkeley AGMs, a Thor notice of meeting, and grab samples from Landore's non-core Nevada ground that look loud but say nothing about tonnage.
Commentary, not advice · written by The Assay desk from the day's RNS · original announcements are linked
The three that mattered
- 1ORR6/10
A scoping study shows ultra-fine grinding instead of an autoclave cuts Bibemi's sulphide plant capex by 38%, bringing initial capex to US$46.7m. It's simpler to finance, although operating cost per ounce is slightly higher. Bibemi is in Cameroon.
- 2NEO5/10
Neo Energy sets out where the regulatory consents stand for taking over Beatrix 4 from Sibanye-Stillwater and moves to phased funding while it looks for an anchor investor. Some approvals are still with the regulator (DMPR).
- 3LND4/10
Grab samples from non-core Nevada properties hit up to 2,300 g/t silver and 6.86% copper. They are selected surface samples, so they say nothing about tonnage.
Grade or Fade
A scoping study shows ultra-fine grinding instead of an autoclave cuts Bibemi's sulphide plant capex by 38%, bringing initial capex to US$46.7m. It's simpler to finance, although operating cost per ounce is slightly higher. Bibemi is in Cameroon.
Neo Energy sets out where the regulatory consents stand for taking over Beatrix 4 from Sibanye-Stillwater and moves to phased funding while it looks for an anchor investor. Some approvals are still with the regulator (DMPR).
Grab samples from non-core Nevada properties hit up to 2,300 g/t silver and 6.86% copper. They are selected surface samples, so they say nothing about tonnage.
Terra North, a spin-out of Fulcrum's investee, reports surface uranium readings up to 0.42% U3O8 in Canada. It's indirect exposure for Fulcrum shareholders.
Africa Desk
- ORRBibemi Gold Project Update · Senegal, Cameroon, Türkiye
A scoping study shows ultra-fine grinding instead of an autoclave cuts Bibemi's sulphide plant capex by 38%, bringing initial capex to US$46.7m. It's simpler to finance, although operating cost per ounce is slightly higher. Bibemi is in Cameroon.
- NEOCorporate Update · South Africa
Neo Energy sets out where the regulatory consents stand for taking over Beatrix 4 from Sibanye-Stillwater and moves to phased funding while it looks for an anchor investor. Some approvals are still with the regulator (DMPR).
- THXNOTICE OF ANNUAL GENERAL MEETING · Nigeria, Senegal, Burkina Faso
AGM set for 10 December (virtual).
- AALDirector/PDMR Shareholding ·
Routine purchases under the share incentive plan.
- SVMLResults of Meeting · Malawi
All AGM resolutions carried.
Everything else
- 15:29
AGM set for 10 December (virtual).
1 - 12:30
Routine purchases under the share incentive plan.
1 - 07:00
Terra North, a spin-out of Fulcrum's investee, reports surface uranium readings up to 0.42% U3O8 in Canada. It's indirect exposure for Fulcrum shareholders.
MiscellaneousOriginal RNS ↗3 - 07:00
Paid-for research note on the trust published by Kepler.
Non Regulatory AnnouncementOriginal RNS ↗1 - 07:00
Fieldwork complete on Focus Xplore's Canadian gold, REE and lithium properties, with early Biscuit Creek lithium results.
MiscellaneousOriginal RNS ↗3 - 07:00
A scoping study shows ultra-fine grinding instead of an autoclave cuts Bibemi's sulphide plant capex by 38%, bringing initial capex to US$46.7m. It's simpler to finance, although operating cost per ounce is slightly higher. Bibemi is in Cameroon.
6 - 07:00
Grab samples from non-core Nevada properties hit up to 2,300 g/t silver and 6.86% copper. They are selected surface samples, so they say nothing about tonnage.
Strategy/Company/Operations UpdateOriginal RNS ↗4 - 07:00
Neo Energy sets out where the regulatory consents stand for taking over Beatrix 4 from Sibanye-Stillwater and moves to phased funding while it looks for an anchor investor. Some approvals are still with the regulator (DMPR).
5 - 07:00
Wolfram signs a non-binding MoU to acquire Ellipses Pharma as a reverse takeover, and would leave mining.
AcquisitionOriginal RNS ↗4